Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-4 of 4

Sort by

Sort Order Select

Journal Articles

Dual transfusion independence and spleen volume reduction is associated with overall survival in patients with myelofibrosis treated with momelotinib: Post hoc analyses of SIMPLIFY-1 and MOMENTUM

Francesca Palandri, Nicolaas Schaap, Jérôme Rey, Nikolas Von Bubnoff, Andreas Reiter, Juan Carlos Hernandez Boluda, Timothy Devos, Bethan Psaila, Donal McLornan, Catherine Ellis, Fulya Sen Nikitas, Shiyuan Zhang, Jessica Lim, Dwaipayan Patnaik, Stephen Oh

Blood (2025) 146 (Supplement 1): 2023.

https://doi.org/10.1182/blood-2025-2023

Published: 2025

Journal Articles

Impact of new or worsening anemia and thrombocytopenia on clinical outcomes in JAK inhibitor–naive myelofibrosis patients treated with ruxolitinib

Vikas Gupta, Francesca Palandri, Jean-Jacques Kiladjian, Bethan Psaila, Bella Vo, Jessica Lim, Fulya Sen Nikitas, Shiyuan Zhang, Tom (sizhu) Liu, Catherine Ellis, Jasmine Sahni, Dwaipayan Patnaik, Stephen Oh, Ruben Mesa

Blood (2025) 146 (Supplement 1): 3809.

https://doi.org/10.1182/blood-2025-3809

Published: 2025

Journal Articles

Impact of hemoglobin improvement with momelotinib on survival in patients with myelofibrosis and anemia: Post hoc analyses of the simplify-1 and momentum trials

Francesca Palandri, Casey O'Connell, Pankit Vachhani, Donal McLornan, Steffen Koschmieder, Juan Carlos Hernandez Boluda, Catherine Ellis, Tom (sizhu) Liu, Shiyuan Zhang, Jessica Lim, Dwaipayan Patnaik, Vikas Gupta

Blood (2025) 146 (Supplement 1): 5581.

https://doi.org/10.1182/blood-2025-5581

Published: 2025

Journal Articles

Survival outcomes in ruxolitinib-treated patients with myelofibrosis following crossover to momelotinib: Application of the response to ruxolitinib at 6 months (RR6) prognostic model to SIMPLIFY-1

Raajit Rampal, Prithviraj Bose, Vikas Gupta, Francesca Palandri, Shiyuan Zhang, Jessica Lim, Fulya Sen Nikitas, Tom (sizhu) Liu, Jasmine Sahni, Catherine Ellis, Dwaipayan Patnaik, Florian Heidel, Francesco Passamonti

Blood (2025) 146 (Supplement 1): 5579.

https://doi.org/10.1182/blood-2025-5579

Published: 2025

Update search

NARROW

Publications

Format

Article Type

Date

Availability

Dual transfusion independence and spleen volume reduction is associated with overall survival in patients with myelofibrosis treated with momelotinib: Post hoc analyses of SIMPLIFY-1 and MOMENTUM

Impact of new or worsening anemia and thrombocytopenia on clinical outcomes in JAK inhibitor–naive myelofibrosis patients treated with ruxolitinib

Impact of hemoglobin improvement with momelotinib on survival in patients with myelofibrosis and anemia: Post hoc analyses of the simplify-1 and momentum trials

Survival outcomes in ruxolitinib-treated patients with myelofibrosis following crossover to momelotinib: Application of the response to ruxolitinib at 6 months (RR6) prognostic model to SIMPLIFY-1

Email alerts

ASH Publications

American Society of Hematology

Update search

Dual transfusion independence and spleen volume reduction is associated with overall survival in patients with myelofibrosis treated with momelotinib: Post hoc analyses of SIMPLIFY-1 and MOMENTUM

Impact of new or worsening anemia and thrombocytopenia on clinical outcomes in JAK inhibitor–naive myelofibrosis patients treated with ruxolitinib

Impact of hemoglobin improvement with momelotinib on survival in patients with myelofibrosis and anemia: Post hoc analyses of the simplify-1 and momentum trials

Survival outcomes in ruxolitinib-treated patients with myelofibrosis following crossover to momelotinib: Application of the response to ruxolitinib at 6 months (RR6) prognostic model to SIMPLIFY-1

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only